Please login to the form below

Not currently logged in
Email:
Password:

Lu AE58054

This page shows the latest Lu AE58054 news and features for those working in and with pharma, biotech and healthcare.

Lundbeck trial failure dashes hopes in Alzheimer's once again

Lundbeck trial failure dashes hopes in Alzheimer's once again

Idalopirdine (Lu AE58054) appeared to be safe and showed evidence of "weak efficacy" in the phase III STARSHINE study, which enrolled patients with mild to moderate Alzheimer's.

Latest news

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Pharma deals during March 2013 Pharma deals during March 2013

    Otsuka will also share development expenses as Lu AE58054 progresses later this year into its pivotal clinical programme comprising several studies and over 2, 500 patients. ... The first phase III study in patients with mild-to-moderate Alzheimer's

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics